Zhittya Regenerative Medicine

[Dpeachey]

A couple of years ago I bumped into this Zhittya company and have followed it closely until now. They reportedly have been working on the FGF-1 molecule ( fibroblast growth factor 1 )for sometime, and are at the human trials stage. My first contact with them, I signed up for possible trials. They indicated they would be paying for all expenses, so I thought, “What the heck, how can I go wrong with that?”

Zhittya is financially at the stage of offering pre- IPOs and plan to soon go public on the New York Stock Exchange. They feel their molecule will become a breakthrough medicine that will change the medical world as much as penicillin did in the 1940s. I’ve been quite excited about it all, and was just about to invest with them, but to make a long story short, while figuring out how to get money from my country to the USA, I began to have my doubts. Spending time researching this company unveiled some interesting things, which I won’t go into detail here. I would just like to put it out there on HU, hoping that some of you wise contributors have done, or can do, some digging into this, and know more than I do about it. I’m an optimist, and don’t mind taking a bit of a risk for the sake of helping medical science progress, but I would hate to be be the pawn of a scam. I look forward to hearing from you!

David.

[ladyaudree]

I found their website a while back and am excited about their totally different approach to a cure. I'll look at them again but I did not notice anything off color about them. Can you post a link to what you found?

[Dpeachey in reply to ladyaudree]

Ladyaudree,

Thanks for your response. I have a host of emails from Dan Montano, the CEO of Zhittya, but the nature of most of them is confidential. You can do a search on him and find a lot of interesting things.

The company that will be handling the initial public offering (IPO) of shares is Roth Capital Partners, LLC, of Newport Beach, California. Dan Montano’s son, Alexander Montano, is the Managing Director of Roth Capital.There’s an interesting documentary on Netflix called “The China Hustle”, and Roth Capital factors into the story.

Investment language is almost like a foreign language to me, so maybe some of you out there in the business world could do a little digging and come back with some insight for us who are not as enlightened. I think I only know enough to get me in trouble. Again, I look forward to hearing from you!

[ladyaudree in reply to Dpeachey]

After googling them I think you are 100% correct about the Montanos and Roth Capital. I am on their email list and might have invested a little in their upcoming IPO. The China Hustle is available for streaming and I will watch it. Thanks

[park_bear in reply to ladyaudree]

See my 2nd comment about investing below.

[Despe]

"Regenerative Medicine of China

for the exclusive rights to market and sell all biological drugs developed by Zhittya during a 30-year time period. . ."

China is everywhere! Why would you buy stock? I firmly believe that, even if ANGIOGENESIS will be the "cure" for PD, from trials to application will be at least 30 years.

[park_bear in reply to Despe]

Looks like that came from here:

zhittyaregenerativemedicine...

I am not about to buy stock either, for several reasons.

However, it looks like the agreement you reference covers China only. I do not see any problem with that.

[Despe in reply to park_bear]

Oh, no, they made agreements with Canada and Europe as well.

[park_bear in reply to Despe]

Yes they did. Standard operating procedure for small biotechs to sell off marketing rights outside the US.

[Despe]

Click away. The most recent is November 2020.

zhittyaregenerativemedicine...

[Despe]

globenewswire.com/news-rele...

[Despe]

parkinsonsnewstoday.com/202...

[park_bear]

This was discussed a few months ago at some length here:

healthunlocked.com/parkinso...

Some red flags:

If their treatment works as intended it will surely be a boon for suffers of peripheral artery disease, where there is great need. On the other hand, nobody else thinks Parkinson's is a circulatory issue. From the point of view of a potential stockholder, initially focusing on Parkinson's and ALS strikes me as a misallocation of funds.

Getting FDA authorization to do a phase 1 should not be hard, but so far they have gone to Mexico instead. If they do not get FDA authorization for trials that will be an obstacle to US approval. US is the most lucrative market.

Portion of new drugs that make it from preclinical to FDA approval is under 10%. For cardiovascular drugs that fraction is under 7%. See:

bio.org/sites/default/files...

No journal publications